Triptorelin - Revision history

Prab: CSV import

2025-02-13T03:46:47Z

CSV import

← Older revision		Revision as of 03:46, 13 February 2025
Line 1:		Line 1:
	{{~~Short description\|A synthetic hormone used in medicine}}~~		{{DISPLAYTITLE:Triptorelin}}
	~~{{Use dmy dates\|date=October 2023~~}}

	[[File:Triptorelin.svg\|thumb\|Chemical structure of ~~triptorelin~~]]		== Overview ==
	'''Triptorelin''' is a [[gonadotropin-releasing hormone agonist]] (GnRH agonist) used in the treatment of hormone-sensitive conditions. It is a synthetic decapeptide analog of the natural ~~[[gonadotropin-releasing hormone]] (~~GnRH~~). Triptorelin~~ is ~~primarily used~~ in the ~~management~~ of [[~~prostate cancer~~]], [[~~endometriosis~~]], and [[~~precocious puberty~~]].		[[File:Triptorelin.svg\|thumb\|right\|Chemical structure of Triptorelin]]
			'''Triptorelin''' is a [[gonadotropin-releasing hormone agonist]] (GnRH agonist) used in the treatment of hormone-sensitive conditions such as [[prostate cancer]], [[endometriosis]], and [[precocious puberty]]. It is a synthetic decapeptide analog of the natural GnRH, which is involved in the regulation of the [[pituitary gland]]'s secretion of [[luteinizing hormone]] (LH) and [[follicle-stimulating hormone]] (FSH).

	==~~Medical uses~~==		== Mechanism of Action ==
	Triptorelin ~~is used~~ in the ~~treatment~~ of ~~several medical~~ conditions:		Triptorelin acts by initially stimulating the release of LH and FSH from the pituitary gland, leading to a temporary increase in [[testosterone]] and [[estrogen]] levels. However, with continuous administration, it causes downregulation of the GnRH receptors in the pituitary, resulting in decreased secretion of LH and FSH. This leads to a significant reduction in the production of sex hormones, such as testosterone in men and estrogen in women, which is beneficial in treating hormone-sensitive conditions.

	* '''Prostate cancer''': Triptorelin is used ~~as part of [[androgen deprivation therapy]] to reduce the levels of [[testosterone]]~~ in the ~~body, which can help slow the growth~~ of ~~prostate cancer cells.~~		== Clinical Uses ==
			Triptorelin is primarily used in the management of:

	* ~~'''Endometriosis'''~~: By ~~suppressing~~ the ~~production~~ of [[~~estrogen~~]], ~~triptorelin can help alleviate~~ the ~~symptoms~~ of ~~endometriosis, a condition where~~ tissue ~~similar~~ to the ~~lining inside~~ the ~~uterus grows outside the uterus~~.		* [[Prostate cancer]]: By reducing testosterone levels, triptorelin helps in slowing the growth of hormone-sensitive prostate cancer.
			* [[Endometriosis]]: It alleviates symptoms by decreasing estrogen levels, which reduces the growth of endometrial tissue.
			* [[Precocious puberty]]: Triptorelin is used to delay the onset of puberty in children with this condition by suppressing the premature release of sex hormones.

	* '''Precocious puberty''': Triptorelin is ~~used to delay early onset puberty in children by suppressing the release of~~ [[~~gonadotropins~~]].		== Administration ==
			Triptorelin is administered via [[intramuscular injection]]. The dosing schedule can vary depending on the condition being treated, with formulations available for monthly or quarterly administration.

	==~~Mechanism of action~~==		== Side Effects ==
	Triptorelin acts as an agonist of the [[gonadotropin-releasing hormone receptor]] (GnRHR). Initially, it stimulates the release of [[luteinizing hormone]] (LH) and [[follicle-stimulating hormone]] (FSH), leading to a temporary increase in [[sex hormone]] levels. However, with continuous administration, it causes downregulation of the GnRHR, resulting in decreased production of ~~LH and FSH, and subsequently, a reduction in sex hormone levels.~~		Common side effects of triptorelin include:

	~~==Side effects==~~		* Hot flashes
	~~Common side effects of triptorelin include hot flashes, decreased~~ libido~~, and mood~~ changes~~. Long-term use can lead to [[osteoporosis]] due to decreased [[bone density]].~~		* Decreased libido
			* Fatigue
			* Mood changes
			* Injection site reactions

	~~==Chemistry==~~		In men, there may be an initial "flare" of symptoms due to the temporary increase in testosterone levels before they decrease.
	~~Triptorelin is a decapeptide with the sequence pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2. It is available in various formulations~~, ~~including depot injections that provide sustained release~~ of the ~~drug over time~~.

	~~==History==~~		== Related Pages ==
	~~Triptorelin was first synthesized in the 1970s and has been used clinically since the 1980s. It is marketed under various brand names, including Decapeptyl and Trelstar.~~

	==Related ~~pages~~==
	* [[Gonadotropin-releasing hormone]]		* [[Gonadotropin-releasing hormone]]
			* [[Luteinizing hormone]]
			* [[Follicle-stimulating hormone]]
	* [[Prostate cancer]]		* [[Prostate cancer]]
	* [[Endometriosis]]		* [[Endometriosis]]
	* [[Precocious puberty]]		* [[Precocious puberty]]

	~~==References==~~		[[Category:Hormonal agents]]
	~~{{Reflist}}~~

	[[Category:~~Hormones~~]]
	[[Category:Peptides]]		[[Category:Peptides]]
	[[Category:~~Prostate cancer treatments]]~~		[[Category:Oncology]]
	~~[[Category:Endometriosis]]~~
	~~[[Category:Puberty~~]]

Prab: CSV import

2025-02-09T11:54:14Z

CSV import

@@ Line 1: / Line 1: @@
-{{intro}}
+[[File:Triptorelin.svg|thumb|Chemical structure of triptorelin]]
-Triptorelin is a gonadotropin releasing hormone (GnRH) agonist that is a potent inhibitor of the synthesis of testosterone (in men) and estrogen (in women) and is used to treat advanced prostate cancer.
+'''Triptorelin''' is a [[gonadotropin-releasing hormone agonist]] (GnRH agonist) used in the treatment of hormone-sensitive conditions. It is a synthetic decapeptide analog of the natural [[gonadotropin-releasing hormone]] (GnRH). Triptorelin is primarily used in the management of [[prostate cancer]], [[endometriosis]], and [[precocious puberty]].
-{{livtox}}
+==Medical uses==
-Triptorelin is associated with a low rate of transient serum enzyme elevations during therapy, but has not been linked convincingly to cases of clinically apparent acute [[liver injury]].
+Triptorelin is used in the treatment of several medical conditions:
-{{fda}}
+* '''Prostate cancer''': Triptorelin is used as part of [[androgen deprivation therapy]] to reduce the levels of [[testosterone]] in the body, which can help slow the growth of prostate cancer cells.
-{{se}}
+* '''Endometriosis''': By suppressing the production of [[estrogen]], triptorelin can help alleviate the symptoms of endometriosis, a condition where tissue similar to the lining inside the uterus grows outside the uterus.
-{{cancer drugs}}
+* '''Precocious puberty''': Triptorelin is used to delay early onset puberty in children by suppressing the release of [[gonadotropins]].
-{{coststubd}}

Prab at 12:28, 19 April 2019

2019-04-19T12:28:08Z

New page

{{intro}}
Triptorelin is a gonadotropin releasing hormone (GnRH) agonist that is a potent inhibitor of the synthesis of testosterone (in men) and estrogen (in women) and is used to treat advanced prostate cancer.

{{livtox}}
Triptorelin is associated with a low rate of transient serum enzyme elevations during therapy, but has not been linked convincingly to cases of clinically apparent acute [[liver injury]].

{{moa}}
Triptorelin (trip" toe rel' in) is a decapeptide analogue of gonadotropin releasing hormone (GnRH) that acts on the pituitary to cause the synthesis and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH), two gonadotropins that act on the male testes to stimulate the production of testosterone and on the female ovaries to induce synthesis of estrogen. Triptorelin and other GnRH agonists cause an initial surge of gonadotropin release, but then lead to down-regulation of their synthesis and secretion which results in a decline in testosterone and estrogen production. Triptorelin, alone or in combination with other antiandrogens, has been found to be palliative in advanced prostate cancer and as effective as surgical castration.

{{fda}}
Triptorelin was approved for use in the United States for prostate cancer in 2000 and is still widely used, being considered a first line [[treatment]] of this hormone responsive malignancy. Triptorelin is available generically and under the brand name Trelstar in an injectable suspension for intramuscular depot administration every 4 weeks (3.75 mg), 12 weeks (11.25 mg) or 24 weeks (22.5 mg). Triptorelin and the other GnRH analogues cause a profound hypogonadism ("chemical castration").

{{se}}
The common [[side effects]] are typical of androgen deprivation, including hot flashes, loss of libido, erectile dysfunction, depression, [[nausea]], [[diarrhea]], weight gain and fluid retention. Rare, but potentially severe adverse events can include immediate hypersensitivity reactions, pituitary apoplexy and, with long term use, weight gain, metabolic changes, diabetes and osteoporosis.

{{cancer drugs}}
{{coststubd}}